Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Fig. 2

CRISPR-Cas9 screen to investigate mediators of cisplatin response in T24 cells. (A) Cell number count differences among different cisplatin/sgRNA combination treatments in the high-content screening assay. (B) Cell number foldchange of different cisplatin and sgRNA combination treatments compared to day 0. Error bar = SD

Back to article page

Molecular Cancer

ISSN: 1476-4598